Afimkibart + Placebo
Phase 3Active 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Moderately to Severely Active Ulcerative Colitis
Conditions
Moderately to Severely Active Ulcerative Colitis
Trial Timeline
Sep 17, 2024 → Jan 30, 2031
NCT ID
NCT06589986About Afimkibart + Placebo
Afimkibart + Placebo is a phase 3 stage product being developed by Chugai Pharmaceutical for Moderately to Severely Active Ulcerative Colitis. The current trial status is active. This product is registered under clinical trial identifier NCT06589986. Target conditions include Moderately to Severely Active Ulcerative Colitis.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (3)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06819891 | Phase 3 | Recruiting |
| NCT06819878 | Phase 3 | Recruiting |
| NCT06589986 | Phase 3 | Active |
Competing Products
7 competing products in Moderately to Severely Active Ulcerative Colitis
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| CT-P13 SC Auto-Injector + Placebo Auto-Injector | Celltrion | Phase 3 | 77 |
| Afimkibart + Placebo | Chugai Pharmaceutical | Phase 3 | 77 |
| Afimkibart + Placebo | Chugai Pharmaceutical | Phase 3 | 77 |
| Afimkibart + Placebo | Roche | Phase 3 | 77 |
| Afimkibart | Roche | Phase 3 | 77 |
| Afimkibart | Roche | Phase 3 | 77 |
| Obefazimod | Abivax | Phase 2 | 49 |